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ABSTRACT
Background Immune checkpoint inhibitors are now 
standard of care treatment for many cancers. Treatment 
failure in metastatic melanoma is often due to tumor 
heterogeneity, which is not easily captured by conventional 
CT or tumor biopsy. The aim of this prospective study 
was to investigate early microstructural and functional 
changes within melanoma metastases following immune 
checkpoint blockade using multiparametric MRI.
Methods Fifteen treatment- naïve metastatic melanoma 
patients (total 27 measurable target lesions) were imaged 
at baseline and following 3 and 12 weeks of treatment 
on immune checkpoint inhibitors using: T
2- weighted 
imaging, diffusion kurtosis imaging, and dynamic contrast- 
enhanced MRI. Treatment timepoint changes in tumor 
cellularity, vascularity, and heterogeneity within individual 
metastases were evaluated and correlated to the clinical 
outcome in each patient based on Response Evaluation 
Criteria in Solid Tumors V.1.1 at 1 year.
Results Differential tumor growth kinetics in response to 
immune checkpoint blockade were measured in individual 
metastases within the same patient, demonstrating 
significant intertumoral heterogeneity in some patients. 
Early detection of tumor cell death or cell loss measured 
by a significant increase in the apparent diffusivity 
(D
app) (p<0.05) was observed in both responding and 
pseudoprogressive lesions after 3 weeks of treatment. 
Tumor heterogeneity, as measured by apparent 
diffusional kurtosis (K
app), was consistently higher in the 
pseudoprogressive and true progressive lesions, compared 
with the responding lesions throughout the first 12 weeks 
of treatment. These preceded tumor regression and 
significant tumor vascularity changes (Ktrans, ve, and vp) 
detected after 12 weeks of immunotherapy (p<0.05).
Conclusions Multiparametric MRI demonstrated potential 
for early detection of successful response to immune 
checkpoint inhibitors in metastatic melanoma.
BACKGROUND
Immune checkpoint inhibitors targeting the 
cytotoxic T- lymphocyte antigen-4 (CTLA-4), 
programmed cell death receptor-1 (PD-1) 
and programmed cell death receptor-1 
ligand (PD- L1) are improving outcomes for 
increasing numbers of patients with solid 
cancers.1 These drugs are now the standard 
of care for treating many cancers including 
metastatic melanoma.2 International trials 
testing anti- PD-1 antibodies alone or in 
combination with anti- CTLA-4 antibodies 
in metastatic melanoma reported objective 
response of up to 58% and only a complete 
response of 11.5% at a median follow- up 
of 12.2–12.5 months.3 Although durable 
remissions are achieved in some patients, 
approximately half of treated patients do 
not respond, while all treated patients are 
at risk of immune- mediated toxicity that 
can be both life changing and life threat-
ening.4 5 In clinical practice, standard CT 
and MRI imaging are used for evaluation of 
treatment response, usually undertaken at 
12 weekly intervals. Assessment of response 
in the first few months can be difficult and 
can be confounded by possible pseudopro-
gression, characterized by the enlargement 
of target measurable metastases followed by 
subsequent regression over time. Biomarkers 
that could aid clinical decisions in the early 
stages of treatment are currently lacking.6
Biomarkers derived from whole blood 
sampling and tumor biopsy do not reflect 
the spatiotemporal dynamics of tumor 
immune response to checkpoint inhibi-
tion due to the marked interpatient, inter-
metastatic and intratumoral heterogeneity 
present in melanoma.7 8 Pseudoprogression 
seen in a small number of patients receiving 
immune checkpoint inhibitors is difficult 
to distinguish from true tumor progression 
using size measurements alone on conven-
tional CT.9 10 Functional imaging techniques 
have the potential to longitudinally charac-
terize individual tumor response to immu-
notherapy and could potentially be used in 
2 Lau D, et al. J Immunother Cancer 2021;9:e003125. doi:10.1136/jitc-2021-003125
Open access 
the future to provide an early and accurate prediction of 
treatment response.
Several approaches have been investigated to date for 
imaging response to immune checkpoint inhibition. Posi-
tron emission tomography (PET) with the glucose analog 
2- deoxy-2-[18F]fluoro- D- glucose (18F- FDG) has shown 
promise for long- term successful response monitoring: 
a complete metabolic response (CMR) with 18F- FDG 
uptake 1 year after commencing treatment is associated 
with an excellent progression- free survival compared with 
those patients who do not show CMR.11 However, it is not 
known whether 18F- FDG PET can detect early response 
to treatment, as it can be particularly difficult to distin-
guish tumor metabolism from glucose uptake associated 
with immune infiltration after the initial introduction of 
immune checkpoint inhibitors.12 Although zirconium-89 
radiolabeled antibodies targeting CD8, PD-1, and PD- L1 
have been developed as tracers for first- in- human trials 
in experimental medicine studies,13–15 these radiolabeled 
approaches are expensive and cannot be easily imple-
mented as routine clinical tools.
MRI is a widely available clinical imaging tool. The tech-
nique is particularly well suited for longitudinal tracking 
of early treatment response, as it does not involve 
exposure to ionizing radiation.16 17 Dynamic contrast- 
enhanced MRI (DCE- MRI) measures properties of tissue 
vasculature18 and is increasingly used in the diagnosis, 
staging, and treatment response assessment of many 
cancers.19 Pharmacokinetic modeling of the T1- weighted 
contrast- enhanced images provide quantitative measure-
ments of tissue perfusion and vascular permeability (see 
online supplemental material for a detailed explanation 
of these parameters). For example, Ktrans is the volume 
transfer coefficient from the blood plasma space into the 
extravascular tumor interstitial space reflecting vascular 
permeability, which has been shown to change following 
successful treatment in a number of cancer types and ther-
apeutic regimens.20 21 ve is the fractional volume of the 
extravascular–extracellular space, and vp is the vascular 
plasma volume. Following immunotherapy, DCE- MRI 
has been shown to detect tumor perfusion or vascular 
permeability as a surrogate biomarker of early tumor 
immune rejection in preclinical models of adoptive T 
cell therapy22 23 and has been foun to distinguish pseudo-
progression from true tumor progression in patients with 
previously irradiated melanoma brain metastases after 
three cycles of ipilimumab.24
Diffusion- weighted imaging (DWI) is a complemen-
tary approach based on the molecular movement of 
water in tissues, which has been widely used for probing 
changes in cell density due to tumor cell death that occur 
following successful treatment in cancer.17 25 An advanced 
DWI approach termed diffusion kurtosis imaging (DKI) 
has been shown to detect tumor cellularity and hetero-
geneity in many cancer types based on the non- Gaussian 
movement of water within the heterogeneous tumor 
microenvironment.26 27 Cell density can be quantified on 
DKI based on the apparent diffusivity of water (Dapp), and 
the microscopic heterogeneity of this water diffusion in 
tissue can be probed using a dimensionless metric termed 
apparent diffusion kurtosis (Kapp). A more detailed expla-
nation of these parameters can be found in online supple-
mental material.27 28
Here, we have used a multiparametric imaging approach 
combining morphological volumetric measurements 
with DCE and DKI to phenotype the microstructural and 
functional changes that occur in melanoma metastases 
before, during, and after treatment with immune check-
point inhibitors.
In this prospective study, early changes in the growth 
kinetics, cellularity, heterogeneity and vascularity of the 
tumor microenvironment following immune check-
point blockade between patients and between intermet-
astatic lesions were evaluated using multiparametric MRI 
(mpMRI). Metastatic melanoma offers a paradigm model 




Patients were recruited for mpMRI as part of the MelRe-
sist study, which evaluated response and resistance 
biomarkers in metastatic melanoma patients undergoing 
systemic therapy. Written informed consent was obtained 
from all patients before enrolment. Patient eligibility 
criteria for undertaking MRI included: (A) clinical diag-
nosis of unresectable and previously untreated metastatic 
melanoma (American Joint Committee on Cancer Stage 
IV); (B) a treatment plan to commence standard immune 
checkpoint inhibitors as first- line therapy for unresectable 
metastatic melanoma; (C) Eastern Cooperative Oncology 
Group performance status score of 0 or 1 and life expec-
tancy of 12 weeks or greater; (D) measurable disease on 
baseline CT (tumor diameter >1 cm); (E) availability of 
recent excised or biopsied tissue samples from metastatic 
tumors for histopathological confirmation; (F) known 
BRAF V600 mutation status; and (G) no contraindication 
to undertaking MRI.
Enrolled patients received one of the following regi-
mens: (A) anti- PD-1 monotherapy, 2 mg/kg or 200 mg 
flat dose of pembrolizumab (Keytruda) every 3 weeks; 
or 3 mg/kg or 240 mg of nivolumab (Opdivo) every 2 
weeks or 480 mg every 4 weeks and (B) combined anti- 
CTLA-4 and anti- PD-1 therapy, 3 mg/kg of ipilimumab 
(Yervoy) plus 1 mg/kg of nivolumab (Opdivo) every 
3 weeks for four cycles followed by nivolumab 240 mg 
every 2 weeks or 480 mg every 4 weeks. All treatments 
were administered by intravenous infusion. Treatment 
continued until disease progression (as defined by the 3 
monthly restaging CT scans), development of unaccept-
able adverse side effects such as autoimmune disorders or 
patient withdrawal of consent. A schematic diagram for 
the mpMRI study flow chart and the clinical characteris-
tics of the study participants are as shown in figure 1 and 
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Figure 1 An mpMRI approach for longitudinal tracking of biological changes within tumors in response to immune checkpoint 
blockade. (A) Schematic diagram of the mpMRI approaches used in this study for monitoring tumor response to immune 
checkpoint blockade. Ktrans measurements on dynamic contrast- enhanced MRI were used to quantify vascular permeability, 
while ve and vp reported on the volume of the extravascular–extracellular and vascular spaces, respectively. Diffusional kurtosis 
imaging, as an advanced form of diffusion- weighted imaging, was used to probe tissue microstructure using the metrics of 
apparent diffusivity (Dapp) as a measure of cellularity and apparent kurtosis (Kapp) for tissue heterogeneity. (B) Study flow chart for 
the melanoma immunotherapy trial (MelResist). mpMRI, multiparametric MRI.
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table 1. Further details on the patient demographics can 
be found in online supplemental table S1.
Magnetic resonance imaging
All patients underwent proton (1H) MRI on a 3.0 Tesla 
system (Discovery MR750, GE Healthcare, Waukesha, 
Wisconsin, USA) using a 32- channel phased- array coil with 
respiratory gating or multiple breath- holds used to reduce 
motion artifacts during image acquisition for lesions 
in the abdomen. The mpMRI protocol included multi-
planar T2- weighted single- shot fast spin- echo anatomical 
imaging, DKI of tumor cellularity and heterogeneity, and 
DCE- MRI of tumor perfusion or vascular permeability. 
Imaging was conducted at three timepoints: within 1 
week prior to starting treatment with immune checkpoint 
inhibitors (baseline MRI); 3 weeks after the first infu-
sion (3- week MRI) and 12 weeks after the start of treat-
ment (12- week MRI) coinciding approximately with the 
first standard- of- care restaging CT response assessment 
at 12 weeks. Further details on the imaging acquisition, 
image processing and analysis can be found in the online 
supplemental material and table S2.
Classification of target melanoma metastases and 
measurement of response
Conventional objective response of the target metastases 
was determined by measuring the best treatment outcome 
at the 12- week restaging CT and reassessed at 1 year if 
the patient survived. Response was evaluated by standard 
Response Evaluation Criteria in Solid Tumors (RECIST) 
V.1.1 guidelines at 12 weeks and 1 year.29
In addition, tumor measurements were assessed using 
MRI during the first 12 weeks. Metastases with at least a 
30% decrease in volume on the 12- week MRI were classi-
fied as responding, metastases with at least a 20% increase 
in volume were identified as true progression, while metas-
tases with at least a 20% increase in volume at the 3- week 
MRI, but which subsequently decreased in >30% on the 
12- week scan, were classified as pseudoprogression.
Statistical analysis
Statistical analysis was performed in GraphPad Prism 
software V.8 (La Jolla, California, USA). All values were 
expressed as median and IQR to account for sample 
size differences between groups. Normality was assessed 
using the Shapiro- Wilk test. Changes in individual lesion 
mpMRI biomarkers over the treatment timepoints were 
evaluated using either paired t- test for normally distrib-
uted data or Wilcoxon matched- pair signed- rank test 
for data with non- parametric distribution. Differences 
between the subgroups of responding, pseudoprogres-
sive, and true progressive lesions were evaluated using 
one- way analysis of variance for normally distributed data, 
or the Kruskal- Wallis test with Dunn’s multiple compar-
ison for non- parametric testing. Spearman’s correlation 
analysis was used for evaluating any relationship between 
the mpMRI biomarkers across treatment timepoints. A 
value of p<0.05 was considered as statistically significant.
RESULTS
Clinical characteristics
Fifteen treatment- naïve patients (10 males, 5 females; 
median age 65 years) were imaged with mpMRI over the 
first 12 weeks of immunotherapy. Ten patients completed 
MRI at all three imaging timepoints (baseline, 3- week and 
12- week MRIs); 5 patients were scanned at baseline and/
or 3 weeks before withdrawal from the trial due to clinical 
reasons such as early disease progression or clinical dete-
rioration incompatible with continuing on the study. An 
Table 1 Clinical characteristics of study participants
Characteristics
No. of patients 15
Age (median age, range) 65.4 (69, 48–76)
Gender 10 males, 5 females
AJCC Stage IV
ECOG performance status
  0 9
  1 6
BRAF status
  BRAF V600 mutant 3
  BRAF Wild- type 12
Serum LDH (IU/mL) at baseline
  Normal (<250) 10
  Elevated (>250) 5
Neutrophils- to- lymphocyte ratio at baseline
  Normal (<5) 12
  High (>5) 3
Immunotherapy, n (%)
  Pembrolizumab 6 (40.0)
  Nivolumab 2 (13.3)
  Combined ipilimumab and nivolumab 7 (46.7)
RECIST 1.1 CT evaluation at 12th week, n (%)
  Partial response 5 (33.3)
  Stable disease 4 (26.7)
  Progressive disease 6 (40.0)
RECIST 1.1 CT evaluation at 1 year, n (%)
Complete response 3 (20.0)
Partial response 4 (26.7)
Progressive disease 8 (53.3)
Anatomical site selected for MRI
  Head and neck 2
  Chest 1
  Abdomen and pelvis 7
  Subcutaneous 4
  Limbs 1
All patients imaged were histologically confirmed as AJCC Stage IV 
melanoma.
AJCC, American Joint Committee on Cancer staging (seventh edition); ECOG, 
Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; RECIST 
1.1, Response Evaluation Criteria in Solid Tumors guidelines V.1.1.
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additional four patients were enrolled on the study but 
were deemed as ineligible for the prospective trial due to 
insufficient time for scheduling of imaging scans before 
the start of treatment (within a week) or target lesions 
that were too small (less than 1 cm in largest diameter) 
for multiple timepoint imaging and follow- up treatment 
response assessment. 53% of the patients received PD-1 
monotherapy, while 47% of the patients were treated with 
combined CTLA-4 and PD-1 therapy.
Differential response to immune checkpoint blockade
Based on RECIST V.1.1 assessment at the 12- week 
restaging CT, five patients demonstrated partial response 
to immune checkpoint inhibitors, four had stable 
disease, and six showed disease progression. The patients 
with stable disease demonstrated differential response 
between the individual metastases. Two out of these four 
patients subsequently progressed at the 1- year restaging 
CT, and the remaining two patients demonstrated 
continued response to treatment (table 1). Consequently, 
at the 1- year timepoint, three patients showed complete 
response, four demonstrated partial response, one was 
alive with progressive disease, and the remaining seven 
had died from progressive disease. Further details on 
patient demographics can be found in online supple-
mental figure 1.
The mpMRI images for a total number of 27 enhancing 
target melanoma metastases that were first identified as 
more than 1 cm in diameter on staging CT were analyzed. 
In this study, a total of 13 responding, 4 pseudoprogres-
sive, and 10 true progressive metastases were identified 
by MRI. Tumors were categorized into three subgroups 
(responding, pseudoprogression, and true progres-
sion) were based on comparing the 3- week MRI with the 
12- week MRI, confirmed with restaging CT at 12 weeks 
and follow- up on the clinical outcome for up to 1 year. 
There were no lesions that showed a 30% decrease in 
volume at the 3- week MRI, which subsequently increased 
in volume at the 12- week MRI or on the restaging CT.
T2- MRI volumetric analysis showed differential inter-
patient and intermetastatic response to immune check-
point blockade. Within the cohort of patients in our 
study, intermetastatic differences in the individual tumor 
growth kinetics were particularly evident in patients 
undergoing anti- PD-1 monotherapy, as compared with 
patients receiving combined CTLA-4 and PD-1 treatment, 
where response was almost immediate at the 3- week MRI 
(figure 2A), which may represent the fact that mono-
therapy takes longer to mount antitumor effects compared 
with combination therapy. Interestingly, increasing T2 
hyperintensity or inflammatory changes were detected 
within all four enlarged pseudoprogressive tumors at 3 
weeks, which resolved at 12 weeks with a corresponding 
reduction in tumor volume (figure 2B and figure 3).
Tumor cell death and changes in heterogeneity in response to 
treatment
Figure 4 and online supplemental figure S1 show the 
changes in tumor cellularity and heterogeneity measured 
on DKI. No significant difference in the average Dapp 
for each patient, as a measure of tumor cell density, was 
detected between the responding and non- responding 
patients at baseline (figure 4A); median Dapp of 1.44 
for responding patients versus 1.33 for non- responding 
patients, p=0.62). There was a significant increase in the 
average Dapp of imaged target metastases for each patient 
representing reduced tumor cellularity (p<0.05) in the 
responding patients at 3 weeks (median Dapp 1.65; IQR 
1.59–1.77) compared with baseline (1.44; IQR 1.26–1.63), 
with a further significant increase at 12 weeks (2.01; IQR 
1.60–2.22). In contrast, there was no significant change in 
Dapp in the tumors of non- responders over the 12 weeks of 
treatment (figure 4B).
Further analysis based on classification of individual 
metastases from all patients into the three subgroups 
of ‘responding’, ‘pseudoprogression’ and ‘true progres-
sion’, showed a significantly lower Dapp, reflecting higher 
tumor cell density at baseline in the pseudoprogressive 
lesions (median 1.17; IQR 1.02–1.20), as compared with 
the responding (median 1.48; IQR 1.44–1.68; p<0.001) 
and true progressive lesions (median 1.44; IQR 1.15–1.82; 
p<0.05). Individual tumors responded differently to treat-
ment: most of the responding and pseudoprogressive 
lesions exhibited a significant percentage increase in Dapp 
at the 3- week MRI relative to baseline, indicating lower 
cellularity in most responding lesions (median increase 
in Dapp by 8.9%; IQR 2.3%–27.6%; p<0.05) and pseu-
doprogressive lesions (median increase by 48.0%; IQR 
45.2%–63.1%; p<0.05). A further increase in Dapp was 
detected within the tumor microenvironment in most 
of the metastases responding at 12 weeks (31.7%; IQR 
1.9%–45.5%; p<0.05). However, one lesion demonstrated 
higher cellularity (increase in Dapp) despite a reduction of 
tumor volume over 12 weeks of treatment; interestingly, 
this lesion subsequently increased in size at the sixth 
month restaging CT and was verified to be a pseudopro-
gressive lesion over a longer timeframe. Higher cellularity 
was also detected on average in the pseudoprogressive 
lesions at 12 weeks compared with the responding lesions, 
despite a reduction in tumor volume, which may reflect a 
later phase of immune infiltration and tumor cell killing 
in these metastases (figures 4 and 5). This patient demon-
strated complete response on RECIST V.1.1 evaluation 
at the 1- year follow- up CT scan. Overall, the Dapp values 
measured from the experimental DKI images correlated 
to the apparent diffusion coefficient (ADC) values 
obtained on clinical DWI for all imaged patients (online 
supplemental figure S2).
No significant difference in microscopic tumor hetero-
geneity at baseline (p=0.27) was detected in the tumors 
of the responders (median Kapp 0.61; IQR 0.51–0.71), 
compared with non- responding patients (median 0.71; 
IQR 0.53–0.86), as detected by the average apparent 
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Figure 2 Interpatient and intermetastatic heterogeneity in response to immune checkpoint blockade. (A) Differential tumor 
growth kinetics in patients receiving PD-1 monotherapy compared with combined CTLA-4 and PD-1 treatment. Individual tumor 
volumes were measured on T2- weighted MRI. Categorization of tumors into three subgroups (responding, pseudoprogression, 
and true progression) were based on comparing the 3- week MRI with the 12- week MRI, confirmed with restaging CT at 12 
weeks and follow- up on the clinical outcome for up to 1 year. (B) Representative T2- weighted images from three patients with 
the classic features of responding, pseudoprogressive, and true progressive lesions. Note the T2 hyperintensity in keeping with 
inflammation in the pseudoprogressive lesion at 3 weeks. CTLA-4, cytotoxic T- lymphocyte antigen-4; PD-1, programmed cell 
death receptor-1.
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kurtosis (Kapp) values from all target lesions for each 
patient obtained concurrently on DKI (online supple-
mental figure S1). A significant reduction in Kapp (p<0.05) 
was detected in the tumors of responding patients at 3 
weeks (median 0.59; IQR 0.51–0.65) compared with base-
line (median 0.61; IQR 0.51–0.71). Further analysis of the 
individual lesions showed a trend towards a higher level 
of tumor heterogeneity, as measured by Kapp, in the pseu-
doprogressive lesions throughout the first 12 weeks of 
treatment (baseline: 0.84; 3 weeks: 0.64; 12 weeks: 0.76) 
compared with the responding lesions (baseline: 0.59; 3 
weeks: 0.54; 12 weeks: 0.56); although this did not reach 
statistical significance, it may reflect underlying immune 
cell infiltration or cell death over the course of treatment. 
As with the results for Dapp, no significant change in Kapp 
was detected in the progressing metastases during the 
first 12 weeks of treatment.
Tumor vascular remodeling following cell death
Figure 6 and online supplemental figure S3 show the 
changes in tumor vascularity and perfusion during 12 
weeks of treatment, as measured by DCE- MRI and contrast 
kinetic modeling using the extended Tofts model. The 
average tumor vascular transfer constant (Ktrans) at base-
line was higher in the target lesions of the responding 
patients (median Ktrans 0.56; IQR 0.23–1.37) compared 
with the non- responders (0.15; IQR 0.11–0.44; p<0.05). 
Similarly, the average fractional extravascular–extracel-
lular volume (ve) at baseline of the target lesions of the 
responding patients were higher (median ve 0.49; IQR 
0.31–0.77) compared with the non- responders (0.19; IQR 
0.15–0.32; p<0.05). A significant reduction in these tumor 
vascularity metrics (Ktrans, ve, and vp) was only detected at 
12 weeks compared with baseline (0.11; IQR 0.05–0.45; 
p<0.05) but not at 3 weeks. A gradual increase in tumor 
vascular metrics was detected in the tumors of non- 
responding patients over the course of treatment, but this 
was not statistically significant, which may reflect the small 
numbers, particularly at the 12- week MRI. Further analysis 
on the individual lesions showed no significant difference 
in the vascular transfer constant Ktrans, fractional volume 
of the extravascular–extracellular space ve, or fractional 
plasma volume vp, between the three subgroups of lesions 
before the start of treatment. A significant decrease in 
Ktrans relative to baseline was detected in most responding 
lesions at 12 weeks (median −66.19%; IQR −92.00 to 
−46.49%; p<0.01) but not at the 3- week MRI (−29.73%; 
IQR −40.51 to 14.01%; p=0.23). Similarly, ve and vp were 
also lower in the responding lesions at 12 weeks (p=0.07 
and p<0.01, respectively). A trend towards lower Ktrans 
was also detected in most pseudoprogressive lesions at 3 
weeks (median 0.47; IQR 0.18–0.60) and 12 weeks (0.15; 
IQR 0.11–0.32), compared with baseline (0.52; IQR 
0.19–0.82), but this was not statistically significant given 
the small number of pseudoprogressive lesions within the 
patient cohort.
Early treatment timepoint changes in tumor cellularity is 
independent of tumor volume
Spearman’s correlation analysis of the mpMRI biomarkers 
over the first 12 weeks of treatment in this cohort showed 
no significant correlation between tumor volume and 
Dapp (online supplemental figure S4). This implies that 
the early detection of changes in tumor cellularity from 
immune cytotoxic killing of tumor cells at the 3- week MRI 
was independent of changes in tumor volume. However, a 
positive correlation was found between tumor volume and 
all metrics of tumor vascularity and perfusion at 12 weeks 
(Ktrans, ve, and vp), suggesting that vascular remodeling 
Figure 3 Histogram analysis of the T2 intensity values of all four pseudoprogressive lesions.
8 These included: the (A) axilla 
lesion 2, (B) axilla lesion 3, (C) subcutaneous lesion of patient 4, and the (D) external iliac node of patient 7.
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Figure 4 Early detection of tumor cell death using DKI. (A) Comparison of apparent diffusivity (Dapp) as a measure of tumor 
cell density between responders and non- responders at baseline before the start of treatment. (B) Changes in average tumor 
Dapp on a per patient basis over the course of treatment, divided according to overall response. (C) Response of individual 
lesions classified into three subgroups (responding, pseudoprogression, and true progression) showing the differences in 
tumor cellularity at baseline. (D) Percentage change in Dapp relative to baseline in individual lesions from the three subgroups. 
(E) Representative Dapp images from three lesions categorized as responding, pseudoprogression, and true progression, 
respectively, based on the 1- year restaging CT. Data are presented as median and IQR. Normality was assessed using the 
Shapiro- Wilk test. Mann- Whitney test was performed to assess differences between two independent lesion subgroups; 
Kruskal- Wallis test with post hoc Dunn’s multiple comparison analysis was performed to test for differences between three 
independent lesion subgroups; *p<0.05; ***p<0.001. Yellow line in figure part D indicates the percentage change in Dapp for 
patient 4. Analysis of apparent kurtosis as a measure of tumor heterogeneity, detected concurrently using DKI, is found in online 
supplemental figure S1. DKI, diffusion kurtosis imaging.
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Figure 5 Dynamic changes in intertumoral response to immune checkpoint blockade within a single patient. (A) Multiple 
metastases in a patient on treatment with nivolumab (PD-1 monotherapy). Intertumoral differences in treatment response, 
vascular permeability, and cellularity were measured in four target lesions on MRI during the first 12 weeks of treatment. 
Increased cellularity was detected in the responding tumor (lesion 1) despite a reduction in tumor volume and lower vascularity 
at 12 weeks. The responding lesion subsequently progressed at 6 months on treatment and was surgically resected. (B) Axial 
CT of lesion 1 at baseline, 12 weeks, and 6 months; largest tumor diameter shown in mm. (C) Immunohistochemistry of lesion 
1 showed remarkable infiltration of immune cells (CD8) in viable tumor tissues that were highly hypoxic (CAIX), proliferative 
(Ki67), and vascular (CD31). Scale bars for CD8 immunostained images represent 100 µm (10× magnification) and 50 µm (80× 
magnification); 100 µm in CAIX/Ki67 dual staining (20× magnification) and CD31 (10× magnification). PD-1, programmed cell 
death receptor-1.
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Figure 6 Tumor vasculature remodeling following immune cytotoxic killing and tumor cell death. (A) Comparison of vascular 
permeability Ktrans between responders and non- responders at baseline before the start of treatment. (B) Changes in tumor 
Ktrans over the course of treatment. (C) Comparison of tumor vascular permeability at baseline between individual lesions 
from the three subgroups: responding, pseudoprogression, and true progression. (D) Percentage change in Ktrans relative to 
baseline in individual lesions from the three subgroups. (E) Representative Ktrans images from the three subgroups lesions. 
*P<0.05; **p<0.01. Yellow line in figure part D indicates the percentage change in Ktrans for patient 4. Analysis for other DCE- MRI 
parametric measurements is found in online supplemental figure S3. DCE- MRI, dynamic contrast- enhanced MRI.
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may be related to tumor size changes following immune 
checkpoint blockade.
DISCUSSION
As immune checkpoint inhibitors become more widely 
used in routine clinical practice, there is an unmet need 
for more effective tools to measure successful response 
to these agents. This is increasingly important as more 
patients with cancer are being offered long term immuno-
therapy, which is costly to healthcare systems and comes 
with a significant risk of side effects. Tumor heterogeneity 
is one of the major challenges for effective cancer treat-
ment and manifest as morphological, functional, cellular, 
metabolic, and molecular diversity.30 31 Clinical tools to 
image this multilayered tumor heterogeneity and how it 
changes with immunotherapy could have a role in differ-
entiating tumor resistance from successful response early 
in the treatment pathway.32
In this study, longitudinal tracking of microstructural 
and functional changes in metastatic melanoma during 
the first 12 weeks of treatment was performed using 
mpMRI. Heterogeneity in response to immune check-
point blockade was observed in these treatment- naïve 
tumors. This heterogeneity may be due to interpatient 
and intermetastatic differences in tumor immunoge-
nicity, as some patients may have more delayed response, 
multiple waves of immune activation or ongoing immune 
evasion and clonal expansion during continuous treat-
ment, as exemplified by patient 4. These changes in the 
tumor microenvironment may not be identified by stan-
dard CT or MRI, as the change in tumor size alone are 
often insufficient to determine treatment benefit at the 
early stages of immunotherapy. Therefore, a clinically 
applicable tool to evaluate immunotherapy is required to 
guide clinical decision making.33
Treatment response to immune checkpoint blockade 
was captured longitudinally on mpMRI in this study using 
three approaches to assess the tumor microenvironment: 
T2- weighted MRI of tissue structure, DKI of cellular 
density and its microscopic heterogeneity, and DCE- MRI 
of the tumor vasculature. An interesting and unexpected 
observation was an increase in median T2- weighted signal 
intensity following 3 weeks of immunotherapy (one infu-
sion of immunotherapy) in the pseudoprogressive metas-
tases, compared with metastases that responded or were 
shown to progress at later timepoints. This is likely to be 
due to tumor enlargement from significant immune cell 
infiltration and inflammation, rather than tumor prolifer-
ation. T2- weighted MRI represents a very simple routine 
clinical tool that may be able to discriminate pseudopro-
gression from true progression if this initial observation 
could be confirmed in larger studies. Quantitative analysis 
of these signal intensity changes, for example, using T2 
mapping, may be useful in future trials for more detailed 
characterization of these microstructural changes.34
Changes in cell density were measured using Dapp on 
DKI to detect either cytotoxic T- cell killing or increased 
cell density from immune infiltration or tumor prolifer-
ation. Cell loss measured as an increase in the median 
Dapp was detected in both responding and pseudoprogres-
sive lesions as early as 3 weeks after the start of treatment 
compared with baseline. Further reductions in cell density 
within the responding lesions were detected at the 12- week 
MRI. An increase in ADC measured on DWI (equivalent 
to the Dapp measured here) has also been reported in 
previously treated ocular melanoma responding to immu-
nostimulatory adenoviral CD40L gene therapy: ≥1 fold 
change in ADC at week 5 following treatment was a better 
predictor of objective survival than metabolic changes on 
18F- FDG PET and tumor size changes on MRI.35 Interest-
ingly, in our study, an increase in cell density (or lower 
Dapp) was detected in the pseudoprogressive lesions at 
12 weeks compared with the responding lesions, despite 
reduced tumor volumes measured on the 12- week MRI 
and standard restaging CT. No significant correlation 
between Dapp and tumor volume was detected across the 
imaging timepoints, which implies that the estimation of 
cell density based on water diffusion within the tumor 
microenvironment is independent of tumor volume and 
is therefore an important additional metric to measure. 
A higher degree of tumor heterogeneity, as assessed by 
an increase in Kapp, was detected in the pseudoprogres-
sive lesions throughout the MRI imaging timepoints, 
compared with the responding lesions. This supports 
the hypothesis that there is underlying cellular alteration 
with different phases of immune activation and prolifer-
ation in the pseudoprogressive lesions over the course of 
treatment. Although there was a higher Kapp in the true 
progressive lesions at all imaging timepoints compared 
with the responding lesions, the feasibility of using DKI 
alone to differentiate true progression from pseudopro-
gression could not be established as the number of non- 
responders with complete MRI scans are limited in the 
metastatic disease setting due to early disease progres-
sion and withdrawal from the trial. Nevertheless, greater 
tumor heterogeneity at baseline (entropy, dissimilarity, 
and contrast texture features) measured on CT radiomics 
has been previously reported in non- responders to PD-1 
monotherapy.36
The tumor vasculature plays a significant role in regu-
lating tumor homeostasis, metastasis, and immune traf-
ficking.37 The vascular networks in malignant tumors are 
typically disorganized with immature, tortuous, and leaky 
blood vessels that are hyperpermeable to intravascular 
contrast agents. DCE- MRI showed a gradual decrease in: 
the tumor vascular permeability Ktrans; the extravascular–
extracellular space ve; and the plasma volume fraction vp 
within the responding lesions. This was more prominent 
at the 12- week MRI when a reduction in tumor burden 
was detected, suggesting that tumor vasculature remod-
eling and shutdown may have occurred following cell 
death caused by cytotoxic T cell killing. This contrasts 
with the effects of antiangiogenic treatments in human 
melanoma xenografts whereby the treatments are more 
directed towards the vascular network and are generally 
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not cytotoxic. Tumor vasculature remodeling as repre-
sented by a lower Ktrans, often precedes cell death and 
reduction in tumor burden, with no significant change 
in cell density measurements such as ve or ADC.
38 Despite 
the small number of pseudoprogressive lesions available 
for analysis in our study, lower Ktrans, ve and vp, with a 
corresponding reduction in tumor volume because of cell 
death, was detectable in most pseudoprogressive lesions 
at 12 weeks. The pseudoprogressive lesions in general 
demonstrated lower vascular permeability and perfusion 
compared with the true progressive lesions at 12 weeks. 
Our findings are in concordance with a previous study 
assessing DCE- MRI melanoma brain metastases study in 
which lower vp was detected in previously irradiated pseu-
doprogressive lesions compared with true progressive 
lesions after three cycles of ipilimumab.24 This suggested 
that DCE- MRI may have utility in distinguishing true 
progressive lesions from treatment- responsive lesions but 
at a later timepoint compared with diffusion measure-
ments. Interestingly, higher Ktrans and ve were detected at 
baseline in all imaged tumors of most patients who were 
responders to immune checkpoint inhibitors compared 
with the non- responders. One explanation could be that 
the differences in tumor vasculature between tumors may 
play a role in determining immune trafficking and subse-
quent immune eradication of tumor cells.37 Ideally, this 
could be explored by tissue sampling of multiple lesions 
both before and during therapy, but this is not practical 
in the metastatic disease setting clinically, and further 
preclinical research is required.
As part of this prospective study, we have demonstrated 
marked intralesional, intermetastatic, and interpatient 
heterogeneity in melanoma over the first 12 weeks of 
immunotherapy. After only 3 weeks of treatment or one 
infusion of immunotherapy, a decrease in cellularity, as 
measured on DKI, could distinguish responding patients 
from non- responders, as well as individual responding 
and pseudoprogressing tumors from true progressing 
ones. An interesting finding was an increase in normal-
ized T2- weighted signal and its distribution in the pseudo-
progressing lesions compared with the progressing lesions 
after 3 weeks treatment. Therefore, combining conven-
tional T2- weighted and DKI at 3 weeks after starting immu-
notherapy could be used to identify pseudoprogression 
during the early stages of treatment. Although there was 
higher tumor vascular permeability and perfusion at base-
line in the responding patients on DCE- MRI compared 
with non- responders, changes in Ktrans could not be used 
to distinguish responding and pseudoprogressing lesions 
until after 12 weeks of treatment showing that measurable 
vascular changes occur later than changes in cellularity.
Our study presented several strengths and limitations. 
This is the first prospective MRI study to serially track 
cellular and functional changes in melanoma metas-
tases during immune checkpoint blockade. As all mela-
noma metastases analyzed in this study were previously 
untreated and unresectable tumors, the treatment time-
point changes measured on mpMRI were directly related 
to immunotherapeutic effects on individual lesions. 
Partial volume effects on image measurements were 
minimal as several patients in our trial presented large 
metastases at baseline. A stringent criterion for imaging 
and analysis was maintained to include only patients with 
measurable disease so that the biological changes were 
trackable over 12 weeks of immunotherapy. Neverthe-
less, our study is limited by the small sample size, which 
restricts the scope for wider interpretation of the results 
and evaluation of the imaging biomarkers for their 
predictive values. Future multicenter trials are required 
to test and validate these imaging biomarkers in a larger 
patient cohort, with the aim of integrating these imaging 
methods into immunotherapy trials and routine clinical 
management. Our study is further limited by the lack of 
radiological–pathological correlation, as relatively few 
metastases are readily accessible to biopsy. This diffi-
culty in obtaining tumor tissues from metastatic sites 
further highlights the strengths of non- invasive imaging 
as a surrogate for pathology as changes in tumor growth 
kinetics, cell density, heterogeneity, and vascularity within 
individual tumors could be longitudinally tracked over 
the course of treatment.
Although no CT was available at the 3- week MRI time-
point for direct comparison, the lesional volume on MRI 
at this early timepoint represents a surrogate for the CT 
size measurements. Using size criteria alone, conven-
tional CT is unlikely to provide additional information 
over MRI. The latter not only provides enhanced soft 
tissue contrast, but importantly can probe quantitative 
measures of tissue function that are not possible with 
CT, thus providing significant biological information as 
we have demonstrated here. Although CT can be used 
to probe tumor perfusion as part of dynamic contrast- 
enhanced CT, this is usually at lower temporal resolution 
and with a significant radiation burden given the multiple 
acquisition timepoints. More generally, the radiation dose 
from CT decreases its suitability for multiple timepoint 
imaging, especially in patients who are particularly at risk 
of radiation effects. The emerging field of radiomics to 
study tissue heterogeneity would also be interesting to 
evaluate on CT at this early 3- week timepoint, but both 
radiomics and CT perfusion are currently research tools 
and require validation within future prospective trials.
In conclusion, mpMRI has shown potential for early 
assessment of response to immunotherapy in metastatic 
melanoma patients. Early changes in tumor cellularity 
measured on DKI following 3 weeks after starting treat-
ment could be used to detect responding and pseudo-
progressive melanoma metastases before a change in 
tumor volume and vascular permeability. This work could 
have important implications for monitoring treatment of 
metastatic melanoma and the increasing number of solid 
cancers treated with immunotherapy.
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